Lead candidate EG-1962, a polymer-based microparticle formulation of the FDA-approved calcium channel inhibitor nimodipine, more than piqued the curiosity of investors, who plowed approximately $72.5 million into Edge Therapeutics Inc. in two follow-on C rounds.